Probiotic

Investigating the effects of B. Subtilis Bacteria on the microbiome in Parkinson’s Disease

Bacillus subtilis PXN21 is a type of beneficial bacteria commonly found in the gut. There is evidence to suggest that the gut microbiome, which includes a diverse community of microorganisms that live in the digestive tract, plays an important role in Parkinson’s disease (PD). Some studies have shown that people with PD have different gut microbiome compositions compared to healthy individuals.

This clinical research study is investigating the effects of B. Subtilis PXN21 on gut microbiome in Parkinson’s disease. The study is recruiting participants with PD and randomly assigning them to either a treatment group or a placebo group. The treatment group will receive B. Subtilis PXN21 in the form of a pill supplement, while the placebo group will receive a similar-looking and tasting product that does not contain the bacteria.

Over the course of the study, researchers will collect stool samples from both groups of participants to analyze changes in gut microbiome composition. They will also assess clinical outcomes such as changes in motor symptoms, cognitive function, and daily living.

The ultimate goal of this study would be to determine whether B. Subtilis PXN21 has any beneficial effects on gut microbiome composition and PD symptoms. If the results are promising, this could lead to the development of new treatments for PD that target the gut microbiome.